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BACKGROUND
It is uncertain whether the duration of red-cell storage affects mortality after 
transfusion among critically ill adults.
METHODS
In an international, multicenter, randomized, double-blind trial, we assigned 
critically ill adults to receive either the freshest available, compatible, allogeneic 
red cells (short-term storage group) or standard-issue (oldest available), compatible, 
allogeneic red cells (long-term storage group). The primary outcome was 90-day 
mortality.
RESULTS
From November 2012 through December 2016, at 59 centers in five countries, 4994 
patients underwent randomization and 4919 (98.5%) were included in the primary 
analysis. Among the 2457 patients in the short-term storage group, the mean stor-
age duration was 11.8 days. Among the 2462 patients in the long-term storage 
group, the mean storage duration was 22.4 days. At 90 days, there were 610 deaths 
(24.8%) in the short-term storage group and 594 (24.1%) in the long-term storage 
group (absolute risk difference, 0.7 percentage points; 95% confidence interval 
[CI], −1.7 to 3.1; P = 0.57). At 180 days, the absolute risk difference was 0.4 percent-
age points (95% CI, −2.1 to 3.0; P = 0.75). Most of the prespecified secondary 
measures showed no significant between-group differences in outcome.
CONCLUSIONS
The age of transfused red cells did not affect 90-day mortality among critically ill 
adults. (Funded by the Australian National Health and Medical Research Council 
and others; TRANSFUSE Australian and New Zealand Clinical Trials Registry 
number, ACTRN12612000453886; ClinicalTrials.gov number, NCT01638416.)
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Red-cell transfusions are common in critically ill patients,1-3 and red cells may be stored for up to 42 days depend-
ing on manufacturing process, additive solution, 
and local policies or regulations.4,5 During stor-
age, red cells undergo structural, biochemical, 
and metabolic changes, known as the “storage 
lesion,”5 and may cause harm.6,7 However, usual 
practice is for blood banks to issue the oldest 
compatible red-cell units available.8
Transfusion of older red cells has been asso-
ciated with increased morbidity and mortality 
among critically ill, surgical, and trauma pa-
tients.6,7 Critically ill patients may be more sensi-
tive than others to any adverse effects associated 
with red-cell storage.6,9,10 The Age of Blood Evalu-
ation (ABLE) trial11 studied 2430 critically ill 
adults with a high risk of death, and the un-
blinded, randomized Informing Fresh versus Old 
Red Cell Management (INFORM) trial12 involved 
unselected hospitalized adults, including 10,578 
patients admitted to the intensive care unit 
(ICU). Both trials showed no significant differ-
ences in outcome between patients who received 
fresher red cells and those who received older 
red cells. In the ABLE trial, approximately 10 
hours elapsed between randomization and first 
transfusion, which may have limited transfusion 
efficacy and decreased between-group differ-
ences. The mortality among the ICU patients in 
the INFORM trial was low, suggesting low ill-
ness severity. The smaller sample size of the 
ABLE trial and the limited outcome data in the 
INFORM trial reduced the capacity of these trials 
to detect small, important signals for harm, to 
evaluate key subgroups, and to rule out differ-
ences in nosocomial infections or transfusion 
reactions. Furthermore, a recent meta-analysis 
including these trials was unable to rule out 
harm from the transfusion of fresher red cells.13
We designed the Standard Issue Transfusion 
versus Fresher Red-Cell Use in Intensive Care 
(TRANSFUSE) trial to compare the effect of the 
freshest available red cells with that of standard-
issue (oldest available) red cells, in 5000 high-
risk critically ill patients. We hypothesized that 
administration of the freshest available red cells 
would result in lower 90-day all-cause mortality 
than administration of standard-issue red cells.
Me thods
Trial Design
The TRANSFUSE trial was a multicenter, random-
ized, double-blind, parallel-group trial that com-
pared the effect on mortality of the freshest 
available, compatible, allogeneic red cells with 
that of standard-issue red cells in critically ill 
patients who received a red-cell transfusion pre-
scribed by their treating physician. We conducted 
the trial in 59 hospital ICUs in five countries: 
Australia (42 ICUs), New Zealand (8), Ireland (6), 
Finland (2), and Saudi Arabia (1).
Before enrollment was completed, we pub-
lished the protocol and statistical analysis plan14 
(also available with the full text of this article at 
NEJM.org). Ethics committees at Monash Uni-
versity and each participating site approved the 
trial before patient enrollment. We applied waiver 
of consent, opt-out consent, or a deferred con-
sent procedure, according to the requirements 
of the human research ethics committees at the 
participating institutions and local law. An inde-
pendent data and safety monitoring committee 
oversaw the trial. The committee reviewed a 
planned interim analysis after 2500 patients had 
reached 90 days of follow-up.14
The Australian National Health and Medical 
Research Council, Australian Red Cross Blood 
Service, Health Research Council of New Zealand, 
and Irish Health Research Board funded the 
trial. The Australian and Finnish Red Cross 
Blood Services, New Zealand Blood Service, Irish 
Blood Transfusion Service, and the blood bank 
of King Abdulaziz Medical City, Riyadh, Saudi 
Arabia, provided support. No commercial entity 
supported this trial. The trial was designed by 
the authors, who vouch for the accuracy and 
completeness of the data and analyses and for 
the fidelity of the trial to the protocol. No one 
who is not an author or a member of the trial 
management committee contributed to the writ-
ing of the manuscript.
Patient Population
Patients 18 years of age or older who were ad-
mitted to a participating ICU, who had an antici-
pated ICU stay of at least 24 hours, and in whom 
the medical staff had decided to transfuse one 
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or more red-cell units were eligible for inclusion. 
Exclusion criteria were previous red-cell transfu-
sion or cardiac surgery during the hospital admis-
sion, hematologic cancer, organ transplantation, 
pregnancy, expected death in less than 24 hours, 
objection to the administration of human blood 
products, participation in a competing study, 
and the opinion of the treating physician that 
randomization would not be in the best interest 
of the patient (lack of equipoise).
Randomization
We concealed treatment-group assignments 
through a computer-generated schedule includ-
ing variable-block randomization in a 1:1 ratio, 
with stratification according to center. To enroll 
patients, clinical ICU staff used a Web-based sys-
tem that assigned a unique identification number. 
When provided with the identification number, 
hospital transfusion services assigned each pa-
tient to the appropriate treatment group accord-
ing to the randomization schedule of the center, 
without the involvement of clinical staff.
We randomly assigned patients to receive either 
the freshest, compatible, allogeneic red-cell units 
available from the transfusion service (short-term 
storage group) or the oldest available, compatible, 
allogeneic red-cell units (long-term storage group). 
After discharge from the ICU, patients continued 
to receive red cells according to their assigned 
treatment group throughout their index hospital 
stay. Red cells were all leukoreduced before stor-
age and resuspended in saline–adenine–glucose–
mannitol additive solution with a 42-day shelf 
life (Australia and Saudi Arabia) or a 35-day 
shelf life (New Zealand, Finland, and Ireland). 
The treating physicians determined the indication 
for transfusion and the timing and number of 
red-cell units to be transfused.
Treatment-group assignments were concealed 
from treating medical and nursing staff, research 
staff, and statisticians. Two staff members who 
were not involved in the direct care of each trial 
patient checked the designated red-cell units for 
that patient and concealed the collection and 
expiration dates from clinical staff using a bag 
with opaque panels or (in New Zealand and Fin-
land) an obscuring sticker. A previously published 
pilot study confirmed the effectiveness of this 
blinding method.15 To ensure an adequate differ-
ence in the duration of red-cell storage between 
the two treatment groups, we assessed the stor-
age duration at each site after 50 patients had 
received a transfusion, with a minimum differ-
ence of 7 days required for ongoing site partici-
pation.
Outcomes
The primary outcome was 90-day all-cause mor-
tality. Secondary outcomes included 28-day mor-
tality, persistent organ dysfunction or death at 
day 28, days alive and free of mechanical ventila-
tion at day 28, days alive and free of renal-replace-
ment therapy at day 28, new bloodstream infec-
tion in the ICU, febrile nonhemolytic transfusion 
reactions, length of stay in the hospital and in 
the ICU, and quality of life at day 180 after ran-
domization. We followed patients until death or 
180 days after randomization. We defined a febrile 
nonhemolytic transfusion reaction as occurring 
when a patient had an unexpected increase in 
temperature of 1°C or more within 4 hours after 
transfusion in the absence of other pyretic 
stimuli. Quality of life at day 180 after random-
ization is not reported here.
Statistical Analysis
We conducted all analyses in accordance with a 
predefined analysis plan.14 With 4664 patients, 
this trial had 90% power to detect an absolute 
difference of 4.2 percentage points (15% relative 
difference) in 90-day all-cause mortality from 
28% with a two-sided P value of 0.05. We esti-
mated the baseline mortality rate from an in-
hospital mortality rate of 25% that was measured 
among patients who met the inclusion criteria 
for the TRANSFUSE trial in a previous observa-
tional study, and we conservatively estimated 
90-day mortality to be 28%.6 We increased our 
planned enrollment to 5000 patients to account 
for an estimated loss to follow-up (<5%) and for 
a single interim analysis.
We performed all analyses on an intention-to-
treat basis unless otherwise indicated, and no 
assumptions were made for missing data. We 
compared the primary outcome of 90-day all-
cause mortality using an unadjusted chi-square 
test for equal proportions, and we report fre-
quency (percentage) per treatment group with a 
risk difference and 95% confidence interval and 
a corresponding odds ratio and 95% confidence 
interval. We conducted sensitivity analyses using 
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hierarchical multiple logistic regression: first, 
we adjusted for the risk of death as assessed by 
means of the Acute Physiology and Chronic 
Health Evaluation (APACHE) III model, hemo-
globin level at randomization, and blood group, 
with patients nested within sites and site treat-
ed as a random effect, and then we adjusted for 
patient age, which was imbalanced between the 
treatment groups at baseline. We assessed the 
duration of patient survival using Cox propor-
tional-hazards regression with data on patients 
censored at 180 days of follow-up or the last 
known point of contact. We visually assessed the 
proportional-hazards assumption across treat-
ment groups using log-cumulative hazard plots. 
We present survival results as Kaplan–Meier sur-
vival curves with a corresponding log-rank test 
for equality of survivor functions across treat-
ment groups.
Prespecified subgroups for the analysis of the 
primary outcome were type O or non–type O blood 
group, APACHE III risk of death below or above 
the median, and Sequential Organ Failure Assess-
ment (SOFA)16 score at baseline below or above 
the median. We determined heterogeneity between 
subgroups by fitting an interaction between treat-
ment and subgroup with the use of logistic re-
gression.
We undertook additional prespecified second-
ary analyses to further assess the effect of stor-
age duration on mortality, by analyzing storage 
duration independently of treatment assignments 
in quartiles and as a continuous variable and by 
comparing outcomes of patients who received 
only the freshest red cells (<8 days old) with 
those of the other patients. No adjustments were 
made for multiple comparisons, and therefore 
P values for results other than the primary out-
come should be interpreted as exploratory.
R esult s
Patients
From November 2012 through December 2016, 
we identified 6353 potentially eligible patients, 
and 4994 underwent randomization. Of the ran-
domly assigned patients, 39 (0.8%) withdrew con-
sent and 36 (0.7%) were lost to follow-up at 90 
days, leaving 4919 (98.5%) included in the primary 
analysis: 2457 in the short-term storage group and 
2462 in the long-term storage group (Fig. 1).
Patient characteristics at baseline were bal-
anced between the two treatment groups, with 
the exception of age (mean [±SD] age, 62.5±16.8 
years in the short-term storage group vs. 
61.4±17.3 years in the long-term storage group; 
P = 0.02) (Table 1). The mean hemoglobin level at 
randomization was 77.4±12.8 g per liter in the 
short-term storage group and 77.3±13.0 g per 
liter in the long-term storage group (Table 1).
Trial Treatment
Patients received a mean of 4.1±6.0 red-cell units 
in the short-term storage group and 4.0±6.2 red-
cell units in the long-term storage group. The 
mean storage duration of transfused red cells was 
11.8±5.3 days in the short-term storage group 
and 22.4±7.5 days in the long-term storage group 
(Table 2), for a mean difference of 10.6 days 
(95% confidence interval [CI], 10.3 to 11.0). The 
distribution of the duration of red-cell storage is 
shown in Figure S1 in the Supplementary Ap-
pendix, available at NEJM.org. The number of 
patients who received other blood products was 
similar in the two groups (Table 2). The median 
time from randomization to first red-cell trans-
fusion was also similar in the two groups: 1.6 
hours (interquartile range, 0.8 to 2.7) in the short-
term storage group and 1.5 hours (interquartile 
range, 0.8 to 2.7) in the long-term storage group 
(Table 2).
Outcomes
At 90 days after randomization, death had oc-
curred in 610 patients (24.8%) in the short-term 
storage group and in 594 (24.1%) in the long-
term storage group (absolute risk difference, 0.7 
percentage points [95% CI, −1.7 to 3.1]; unad-
justed odds ratio, 1.04 [95% CI, 0.91 to 1.18]; 
P = 0.57) (Fig. 2). Adjustment for the four pre-
defined baseline variables did not substantially 
alter this result (adjusted odds ratio, 1.05; 95% 
CI, 0.92 to 1.21; P = 0.46). Further adjustment for 
patient age in addition to the predefined vari-
ables also did not substantially alter the results 
(Table S5 in the Supplementary Appendix).
There were no significant between-group dif-
ferences in 28-day mortality; the rates of persis-
tent organ dysfunction or death at day 28, new 
bloodstream infections, mechanical ventilation, 
and renal-replacement therapy; or ICU length of 
stay (Fig. 2). Febrile nonhemolytic transfusion 
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reactions occurred more frequently in the short-
term storage group than in the long-term storage 
group (123 events [5.0%] vs. 88 events [3.6%]; 
absolute risk difference, 1.4 percentage points 
[95% CI, 0.3 to 2.6]; unadjusted odds ratio, 1.42 
[95% CI, 1.07 to 1.88]; P = 0.01) (Fig. 2). After 
adjustment, the results were similar (adjusted 
odds ratio, 1.45; 95% CI, 1.09 to 1.93; P = 0.01). 
At 180 days after randomization, death had oc-
curred in 687 of 2410 patients (28.5%) in the 
short-term storage group and in 678 of 2414 
patients (28.1%) in the long-term storage group 
(absolute risk difference, 0.4 percentage points 
[95% CI, −2.1 to 3.0]; odds ratio, 1.02 [95% CI, 
0.90 to 1.16]; P = 0.75) (Fig. 2). Survival time 
according to treatment assignment is shown in 
Figure 3.
Subgroups
The effect of red-cell storage duration on 90-day 
mortality differed significantly according to 
APACHE III risk of death (P = 0.03 for heteroge-
neity). Patients who received the freshest avail-
able red cells had higher mortality in the sub-
group with an APACHE III predicted risk of 
death at hospital discharge equal to or above the 
Figure 1. Randomization and Follow-up.
ICU denotes intensive care unit.
4994 Underwent randomization
6353 Patients were assessed
for eligibility
1359 Were excluded
1353 Were eligible but did not undergo
randomization
1280 Were overlooked for enrollment by ICU
staff 
7 Had clinician who declined to participate
16 Required urgent transfusion or
blood that had not been cross-matched
5 Had alloantibodies present
21 Were previously assigned cross-matched
blood
17 Declined to participate or did not 
provide consent
4 Were to be transferred from trial ICU
3 Had unknown reason
6 Underwent duplicate randomization
during second ICU admission
2490 Were assigned to the short-term
storage group
2454 Received assigned treatment
36 Received one or more standard-
issue red-cell units
2504 Were assigned to the long-term
storage group
2491 Received assigned treatment
13 Received one or more freshest
available red-cell units
33 Were excluded at 90-day
follow-up
14 Withdrew consent
19 Were lost to follow-up
42 Were excluded at 90-day
follow-up
25 Withdrew consent
17 Were lost to follow-up
2457 Were included in the 90-day
mortality analysis
2462 Were included in the 90-day
mortality analysis
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Characteristic
Short-Term Storage 
(N = 2457)
Long-Term Storage 
(N = 2462)
All Patients 
(N = 4919)
Age — yr 62.5±16.8 61.4±17.3 62.0±17.1
Male sex — no. (%) 1311 (53.4) 1258 (51.1) 2569 (52.2)
Primary diagnosis — no. (%)†
Cardiovascular condition 326 (13.3) 342 (13.9) 668 (13.6)
Respiratory condition 413 (16.8) 422 (17.1) 835 (17.0)
Gastrointestinal condition 551 (22.4) 514 (20.9) 1065 (21.7)
Neurologic condition 177 (7.2) 195 (7.9) 372 (7.6)
Sepsis 413 (16.8) 396 (16.1) 809 (16.4)
Trauma 240 (9.8) 262 (10.6) 502 (10.2)
Metabolic condition 68 (2.8) 71 (2.9) 139 (2.8)
Musculoskeletal condition 103 (4.2) 110 (4.5) 213 (4.3)
Renal condition 110 (4.5) 109 (4.4) 219 (4.5)
Other condition 51 (2.1) 35 (1.4) 86 (1.7)
Missing data 5 (0.2) 6 (0.2) 11 (0.2)
≥1 Coexisting condition — no. (%)‡ 860 (35.0) 842 (34.2) 1702 (34.6)
APACHE III score§¶ 72.6±29.2 73.2±29.6 72.9±29.4
APACHE III risk of death — %¶
Median 20.9 22.0 21.5
IQR 8.5–46.0 8.7–46.7 8.6–46.5
SOFA score — median (IQR)¶‖ 7 (4–10) 7 (5–10) 7 (5–10)
Organ support at randomization — no. (%)
Invasive mechanical ventilation 1219 (49.6) 1267 (51.5) 2486 (50.5)
Renal-replacement therapy 342 (13.9) 360 (14.6) 702 (14.3)
ABO blood group — no. (%)
Group A 928 (37.8) 961 (39.0) 1889 (38.4)
Group B 310 (12.6) 303 (12.3) 613 (12.5)
Group O 1126 (45.8) 1105 (44.9) 2231 (45.4)
Group AB 92 (3.7) 93 (3.8) 185 (3.8)
Missing data 1 (<0.1) 0 1 (<0.1)
Hemoglobin at ICU admission — g/liter 102±23.1 102±23.6 102±23.3
Hemoglobin at randomization — g/liter 77.4±12.8 77.3±13.0 77.3±12.9
*  Plus–minus values are means ±SD. There were no significant differences between the two treatment groups in any base-
line characteristic except age (P = 0.02). Percentages may not sum to 100 because of rounding. ICU denotes intensive 
care unit, and IQR interquartile range.
†  The primary diagnosis was classified according to the Acute Physiology and Chronic Health Evaluation (APACHE) III–J 
(Australian and New Zealand Intensive Care Society modified) diagnostic code.
‡  These conditions include a history of cardiac disease, an acute coronary syndrome, or an immunocompromised state 
during the index admission.
§  APACHE III scores range from 0 to 299, with higher scores indicating a higher probability of death.
¶  The APACHE III predicted risk of death at hospital discharge was calculated on the basis of variables measured in the 
first 24 hours of each hospital admission (before randomization).
‖  Sequential Organ Failure Assessment (SOFA) scores range from 0 to 24, with higher scores indicating a greater severity 
of organ dysfunction in critically ill patients.
Table 1. Characteristics of the Patients at Baseline.*
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median of 21.5% (odds ratio, 1.18; 95% CI, 1.00 
to 1.39; P = 0.05) and lower mortality in the sub-
group with a risk of death below the median 
(odds ratio, 0.86; 95% CI, 0.68 to 1.08; P = 0.20). 
We observed no significant differences in the 
other subgroups (Fig. 2).
Secondary Analyses
The 90-day mortality in the quartile of all patients 
who received red cells with the oldest mean age 
did not differ significantly from that in the 
quartiles of patients who received fresher red 
cells. The mortality in each of the prespecified 
mean red-cell age quartiles was, from freshest to 
oldest, 22.9% (95% CI, 20.4 to 25.3), 24.9% (95% 
CI, 22.4 to 27.4), 25.3% (95% CI, 22.7 to 27.8), 
and 23.7% (95% CI, 21.2 to 26.1) (Table S6 in the 
Supplementary Appendix). Mortality did not dif-
fer significantly between patients who received 
only red cells less than 8 days old and other 
patients or between patients who received only 
red cells more than 35 days old and other pa-
tients (Tables S7 and S8 in the Supplementary 
Appendix). We also found no significant asso-
ciation between red-cell age (mean, minimum, or 
maximum) considered as a continuous variable 
and 90-day mortality (Table S9 in the Supple-
mentary Appendix).
Discussion
In our randomized trial involving 4994 critically 
ill adults undergoing transfusion, we found no 
significant difference in 90-day mortality accord-
ing to the duration of red-cell storage. There was 
no benefit associated with the freshest available 
red cells with regard to the primary or second-
ary outcomes, either overall or in most sub-
groups. Among the many secondary outcomes 
tested, we noted a nominal difference in febrile 
nonhemolytic transfusion reactions that was 
small, and we are not sure of its clinical signifi-
cance.
In 14 previous randomized, controlled trials 
comparing outcomes of transfusion of red cells 
with different storage durations,12,17,18 only 2 had 
large sample sizes and included critically ill pa-
tients. The INFORM trial showed no significant 
difference in in-hospital mortality among un-
selected hospitalized patients, and among the 
10,578 patients admitted to the ICU, the 95% CI 
for the odds ratio for death in the hospital was 
0.92 to 1.17.12 The lower in-hospital mortality in 
the ICU subgroup in the INFORM trial (13.0%) 
than that observed in our trial at 90 days (24.5%) 
is consistent with lower illness severity in the 
INFORM patients. The ABLE trial involved 2430 
Characteristic
Short-Term Storage 
(N = 2457)
Long-Term Storage 
(N = 2462) P Value
Patients who received ≥1 red-cell unit — no. (%) 2395 (97.5) 2402 (97.6) 0.85
No. of red-cell units transfused per patient — median (IQR) 2 (1–4) 2 (1–4) 0.89
Pretransfusion hemoglobin — g/liter† 74.4±9.8 74.3±10.2 0.55
Duration of storage of red-cell units per patient — days‡
Mean 11.8±5.3 22.4±7.5 <0.001
Median (IQR) 10.7 (8.3–14.1) 21.4 (16.7–27.4) <0.001
Time from randomization to first red-cell transfusion — hr
Median 1.6 1.5 0.38
IQR 0.8–2.7 0.8–2.7
Patients receiving transfusion of other blood components  
— no. (%)
Platelets 226 (9.2) 198 (8.0) 0.15
Fresh frozen plasma 292 (11.9) 257 (10.4) 0.11
Cryoprecipitate 91 (3.7) 70 (2.8) 0.09
*  Plus–minus values are means ±SD.
†  Shown is the mean hemoglobin level before all episodes of red-cell transfusion.
‡  The arithmetic mean of red-cell storage duration was calculated for each patient.
Table 2. Transfusion Characteristics.*
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critically ill patients and showed no significant 
between-group differences in 90-day mortality 
or secondary outcomes. In that trial, the age of 
red cells in the fresh-blood group was specified 
as less than 8 days. This requirement excluded 
698 potentially eligible patients. Our trial avoided 
this limitation. Furthermore, in the ABLE trial, 
the mean time from randomization until the first 
red-cell transfusion was 10.3 hours in the fresh-
blood group and 9.7 hours in the standard-blood 
group.11 In the TRANSFUSE trial, these times 
were much shorter (1.6 hours and 1.5 hours, 
respectively).
The point estimates for mortality in previous 
randomized trials have actually favored longer 
durations of storage.13 The findings in our trial 
were similar. We found no significant between-
group difference in rates of new bloodstream 
infections. Among patients who were more se-
verely ill (with an APACHE III risk of death equal 
to or above the median), those who received the 
freshest available red cells had a higher mortal-
ity than those who received standard-issue red 
cells. Among all patients, the rate of febrile 
nonhemolytic transfusion reactions was higher 
in the short-term storage group than in the long-
term storage group. However, these should be 
considered exploratory findings. A potential 
mechanism for the higher rate of febrile non-
hemolytic transfusion reactions is damage-asso-
ciated molecular patterns, including those involv-
ing mitochondrial DNA, which accumulate early 
during red-cell storage (within 1 to 2 weeks).19 
These have been associated with febrile non-
hemolytic transfusion reactions20,21 and the acute 
respiratory distress syndrome after transfusion.22 
Our findings reinforce the need for further inves-
tigation into factors that affect red-cell quality.
The trial included a generalizable patient 
population from 59 sites in five countries. The 
pragmatic feature of using the available red-cell 
inventory resulted in a substantial difference in 
storage duration of 10.6 days between the two 
treatment groups and a short time from random-
ization to transfusion. Pretransfusion hemoglo-
bin levels closely approximated those in interna-
tional guidelines, suggesting that transfusion 
practice was similar across the different sites 
and countries. Only 1% of our patients did not 
receive their assigned red-cell transfusion, as 
compared with approximately 12% in the fresh-
blood group of the ABLE trial.11 Our observed 
mortality rate was close to expected and, com-
bined with the large sample size, ensured 90% 
power to detect a difference of 4.2 percentage 
points in 90-day mortality. We minimized bias 
through a blinding procedure that involved pa-
tients, clinical staff, and outcome assessors and 
through concealment of the assigned treatments 
at randomization. There was a low rate of loss to 
follow-up (<1%) and a high ratio of randomly 
assigned patients to eligible patients (0.79:1).
Our design had some limitations. The red-cell 
age in each treatment group was not prespeci-
fied but was determined by the blood-bank in-
ventory at each institution. We did not design 
the trial to assign red cells toward the end of 
their shelf life (35 to 42 days). Although our 
prespecified secondary analysis showed no ef-
fect on mortality in patients who received the 
oldest red-cell quartile or those who received 
only red cells older than 35 days, there were 
relatively few patients who received red cells 
older than 35 days.
Our trial provides strong evidence that trans-
fusion of the freshest available red cells as com-
pared with standard-issue (oldest available) red 
cells provides no clinically meaningful benefits 
in critically ill patients. Our results support the 
current international usual practice of transfus-
ing patients with the oldest red cells available.
In conclusion, we found no significant differ-
ence in the rate of death among critically ill 
Figure 3. Kaplan–Meier Survival Analysis of Time to Death.
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patients who received transfusion of the freshest 
available red cells and those who received stan-
dard-issue, oldest available red cells.
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